Insights on Navigating the Complex Waters in R/R MM - priME Oncology
Webcast
Webcast

Insights on Navigating the Complex Waters in R/R MM

Not a member of My prIME? Join now for instant access.

Learn about currently approved therapies and new targets for patients with either transplant-eligible or transplant-ineligible relapsed/refractory multiple myeloma (R/R MM), as well as common treatment-emergent adverse events associated with different classes of therapeutic agents. This activity features expert faculty video presentations with downloadable slides from our satellite symposium held in conjunction with the 22nd Congress of the European Hematology Association in Madrid, Spain.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.75 AMA PRA Category 1 Credits™

Release Date

Release Date

Jul 21, 2017

Expiration Date

Jul 21, 2018

Looking back to shore: How did we get to R/R MM?
Philippe Moreau, MD 

Wind in our sails: Next-generation therapeutic options in R/R MM
Meletios Dimopoulos, MD 

What’s on the near horizon? New targets in R/R MM
Sagar Lonial, MD

Avoiding treacherous waters: Balancing efficacy with adversity
Enrique Ocio, MD, PhD 

Conclusion and key points
Meletios Dimopoulos, MD

FACULTY

  • Meletios Dimopoulos, MDUniversity of Athens
    Athens, Greece
  • Sagar Lonial, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States
  • Philippe Moreau, MDUniversity of Nantes
    Nantes, France
  • Enrique Ocio, MD, PhDUniversity of Salamanca
    Salamanca, Spain

This educational activity is designed for hematologists, oncologists, patient advocates, and other healthcare providers involved and/or interested in the management of patients with multiple myeloma (MM).

  • Distinguish initial therapeutic strategies for patients who are transplant-eligible versus patients who are transplant-ineligible in the newly diagnosed MM setting
  • Describe the pivotal trials that have led to recent approval of therapies in R/R MM
  • Summarize new targets for therapy in R/R MM currently in late phase clinical trials
  • Identify the common treatment-emergent adverse events associated with different classes of therapeutic agents used in R/R MM

This educational activity is supported by Celgene, Karyopharm Therapeutics, and PharmaMar.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Insights on Navigating the Complex Waters in R/R MM - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Dimopoulos has disclosed that he has received consulting fees from Amgen, Celgene, Janssen, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lonial has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, and Takeda. He has also received contracted research or research support from Bristol-Myers Squibb, Celgene, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Moreau has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ocio has disclosed that he has received contracted research or research support from Amgen, Array Pharmaceuticals, Celgene, and Mundipharma. He has also received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda. Dr Ocio has also received consulting fees from Abbvie, Novartis, PharmaMar, Seattle Genetics, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.